Form 4: BioCryst Pharmaceuticals Director Steven Frank Receives Automatic Equity Grants

BioCryst Pharmaceuticals, Inc. Director Steven Frank was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

Summary

• Steven Frank, a Director at BioCryst Pharmaceuticals Inc. (BCRX), received an automatic grant of equity securities on June 12, 2025.
• The grant included 12,500 shares of Common Stock in the form of Restricted Stock Units (RSUs), which will vest on the first anniversary of the grant date.
• Additionally, Mr. Frank was granted 27,181 stock options with an exercise price of $10.4 per share.
• These stock options become exercisable on June 12, 2026, and expire on June 12, 2035.
• Both grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.
• Following these transactions, Mr. Frank beneficially owns 14,699 shares of Common Stock directly and 27,181 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine, automatic equity grant to a director, which is a positive sign of aligning director incentives with shareholder interests and standard corporate governance. It does not contain any negative news or unexpected events.

Positives

• The grants align director incentives with shareholder interests through equity ownership.
• The automatic nature of the grants indicates a pre-established, transparent compensation policy for non-employee directors.

Future Outlook

This document is a routine insider transaction report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting and exercisability dates of the granted equity.

Industry Context

BioCryst Pharmaceuticals is a biotechnology company focused on developing and commercializing novel, oral medicines for rare diseases. Director equity grants, such as those reported in this Form 4, are a standard practice across the biotechnology and pharmaceutical industries to attract and retain experienced board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The practice of granting Restricted Stock Units (RSUs) and stock options to non-employee directors is a common compensation method in the biotechnology and pharmaceutical sectors, aligning director incentives with shareholder value.
• While specific grant sizes vary by company size, stage, and individual director responsibilities, the structure of automatic grants pursuant to a compensation policy is standard for public companies like BioCryst.
• For example, similar compensation structures are observed at comparable rare disease biotechs such as Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY), where equity forms a significant portion of non-executive director remuneration to foster long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The equity grants to Steven Frank, a director of BioCryst Pharmaceuticals, constitute a related party transaction as it involves compensation to a member of the company's board. This is a standard and disclosed transaction.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with long-term shareholder value creation.

Next Steps

• The Restricted Stock Units are scheduled to vest on June 12, 2026.
• The stock options will become exercisable on June 12, 2026.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, SEC Form 4, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Steven Frank, Non-Employee Director, Insider Trading